Keywords
Percutaneous Coronary Intervention ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

9 Search results.

ICHOM Coronary Artery Disease - Peri-Inverventional Clinical Form

- 11/22/18 - 1 form, 8 itemgroups, 46 items, 1 language
Itemgroups: Administrative Data, Demographic factors, Baseline health status, Prior Treatments, TREATMENT VARIABLES, Acute complications of treatment, Major surgery complications, Major interventional cardiology complications
CORONARY ARTERY DISEASE DATA COLLECTION Version 2.0.3 Revised: April 5th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Conditions: Asymptomatic Coronary Artery Disease | Stable Angina | Acute Coronary Syndrome (Includes AMI) Treatment Approaches: Lifestyle Modification | Drug Therapy | Percutaneous Coronary Intervention (PCI) | Coronary Artery Bypass Grafting (CABG) This form contains peri-interventional clinical items. The items cover a timespan from prior to the intervention (e.g. PCI or CABG) until 30 days after it. They should be assessed at the entry event and at any new index event (e.g. new revascularization procedure or new diagnosis of ACS). Questionnaires used in this standard set: Rose Dyspnea Scale: The Rose Dyspnea Scale is free for all health care organizations, and a license is not needed. More information may be found at http://www.ahjonline.com/article/S0002-8703(09)00266-X/abstract Patient Health Questionnaire (PHQ-2): The PHQ-2 is free for all health care organizations, and a license is not needed. Copyright Pfizer, more Information on http://www.phqscreeners.com/ Seattle Angina Questionnaire (SAQ-7): Due to the need for a license for use of the SAQ-7 the actual questions of SAQ-7 will not be part of this version of the standard set. Publication: McNamara RL, Spatz ES, Kelley TA, et al. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). J Am Heart Assoc. 2015;4(5):e001767. Published 2015 May 19. doi:10.1161/JAHA.115.001767

Quality Assurance Coronary Angiography and Percuteanous Intervention (PCI) - Basic (AQUA) - Quality assurance Coronary Angiography and Percuteanous Intervention (PCI) - Basic (AQUA)

- 8/12/15 - 1 form, 5 itemgroups, 32 items, 2 languages
Itemgroups: Basisdokumentation, Patient, Aktuelle kardiale Anamnese(vor der ersten Prozedur), Verlauf, Entlassung
Documentation form for quality assurance in German Health Care by the Institute for Applied Quality Improvement and Research in Health Care (Aqua), https://www.aqua-institut.de/en/home. Internal Aqua form version: 21-3-B Specification 2015 V02

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Re-Intervention Report

- 10/1/18 - 1 form, 5 itemgroups, 50 items, 1 language
Itemgroups: Administrative Data, Interventional Procedure; Report, Coronary Angiography, Repeat Surgery; Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Hospital Discharge Visit

- 10/1/18 - 1 form, 5 itemgroups, 39 items, 1 language
Itemgroups: Administrative Data, Follow-Up Visit, Adverse Event, Interventional procedure, Since, Percutaneous Coronary Intervention, Concomitant Agent
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Hospital Discharge Visit

- 9/30/18 - 1 form, 5 itemgroups, 43 items, 1 language
Itemgroups: Administrative Data, Discharge Status, Hospitals, Adverse Event, Interventional procedure, Since, Percutaneous Coronary Intervention, Concomitant Agent
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Index PCI Form

- 9/30/18 - 1 form, 4 itemgroups, 70 items, 1 language
Itemgroups: Administrative Data, History of percutaneous coronary intervention, Culprit lesion of coronary artery, Coronary angiography, Result, During Index PCI, Laboratory, Status post, Percutaneous Coronary Intervention; Electrocardiography, Status post; Percutaneous Coronary Intervention
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Blinded Anticoagulation Form

- 8/28/18 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Administrative Data, Study Drug Accountability, ACT Measurement
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Baseline Form

- 8/28/18 - 1 form, 5 itemgroups, 62 items, 1 language
Itemgroups: Administrative Data, Patient Information, Clinical Assessment Pre-Randomization, Pre-Randomization Laboratory Tests, Patient History
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

30-day PCI readmission risk score

- 1/25/18 - 1 form, 1 itemgroup, 12 items, 1 language
Itemgroup: 30-day PCI readmission risk score
On the basis of a preprocedural prediction model for 30-day all-cause readmission of patients undergoing percutaneous coronary intervention (PCI), a simplified score has been derived to predict 30-day readmission risk. References: Wasfy, J. H., Rosenfield, K., Zelevinsky, K., Sakhuja, R., Lovett, A., Spertus, J. A., ... & Yeh, R. W. (2013). A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circulation: Cardiovascular Quality and Outcomes, 6(4), 429-435. http://www.massdac.org/riskcalc_readm30day